
Genentech Reports High-Dose Ocrelizumab Fails to Show Additional Benefit in Relapsing MS
According to a new announcement, the phase 3 MUSETTE trial (NCT04544436) evaluating a higher dose of ocrelizumab (Ocrevus; Genentech) for relapsing multiple sclerosis (RMS) failed to show added benefit in slowing disability progression compared with the …